[go: up one dir, main page]

DZ3049A1 - Suspensions de ziprasidone nouvelles et procédé pour leur préparation. - Google Patents

Suspensions de ziprasidone nouvelles et procédé pour leur préparation.

Info

Publication number
DZ3049A1
DZ3049A1 DZ000093A DZ000093A DZ3049A1 DZ 3049 A1 DZ3049 A1 DZ 3049A1 DZ 000093 A DZ000093 A DZ 000093A DZ 000093 A DZ000093 A DZ 000093A DZ 3049 A1 DZ3049 A1 DZ 3049A1
Authority
DZ
Algeria
Prior art keywords
ziprasidone
suspensions
preparation
new
ziprasidone suspensions
Prior art date
Application number
DZ000093A
Other languages
English (en)
French (fr)
Inventor
Daniel Ray Arenson
Hong Qi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ3049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ3049A1 publication Critical patent/DZ3049A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)
  • Dental Preparations (AREA)
  • General Preparation And Processing Of Foods (AREA)
DZ000093A 1999-05-27 2000-05-24 Suspensions de ziprasidone nouvelles et procédé pour leur préparation. DZ3049A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
DZ3049A1 true DZ3049A1 (fr) 2004-03-27

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ000093A DZ3049A1 (fr) 1999-05-27 2000-05-24 Suspensions de ziprasidone nouvelles et procédé pour leur préparation.

Country Status (50)

Country Link
EP (1) EP1181018B1 (et)
JP (1) JP3942827B2 (et)
KR (1) KR100477782B1 (et)
CN (1) CN1196486C (et)
AP (1) AP1409A (et)
AR (1) AR022643A1 (et)
AT (1) ATE234097T1 (et)
AU (1) AU777413B2 (et)
BG (1) BG65367B1 (et)
BR (1) BR0010990A (et)
CA (1) CA2371550C (et)
CO (1) CO5170458A1 (et)
CR (1) CR6506A (et)
CU (1) CU23223B7 (et)
CZ (1) CZ20014230A3 (et)
DE (1) DE60001649T2 (et)
DK (1) DK1181018T3 (et)
DZ (1) DZ3049A1 (et)
EA (1) EA003907B1 (et)
EE (1) EE04704B1 (et)
ES (1) ES2191618T3 (et)
GC (1) GC0000190A (et)
GE (1) GEP20033113B (et)
GT (1) GT200000081A (et)
HK (1) HK1046366B (et)
HN (1) HN2000000071A (et)
HR (1) HRP20010878B1 (et)
HU (1) HUP0201297A3 (et)
IL (2) IL145950A0 (et)
IS (1) IS2396B (et)
MA (1) MA26741A1 (et)
MX (1) MXPA01012124A (et)
MY (1) MY127891A (et)
NO (1) NO320296B1 (et)
NZ (1) NZ514764A (et)
OA (1) OA11946A (et)
PA (1) PA8495801A1 (et)
PE (1) PE20010127A1 (et)
PL (1) PL196867B1 (et)
RS (1) RS50089B (et)
SI (1) SI1181018T1 (et)
SK (1) SK284590B6 (et)
SV (1) SV2001000085A (et)
TN (1) TNSN00112A1 (et)
TR (1) TR200103392T2 (et)
TW (1) TWI263498B (et)
UA (1) UA59491C2 (et)
UY (1) UY26166A1 (et)
WO (1) WO2000072847A1 (et)
ZA (1) ZA200109692B (et)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
CN102716101A (zh) 1999-10-29 2012-10-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
NZ534746A (en) * 2002-03-12 2006-06-30 Bristol Myers Squibb Co Palatable oral suspension and method
JP2006505579A (ja) * 2002-10-25 2006-02-16 ファイザー・プロダクツ・インク 懸濁形態でのアリール複素環活性薬物の蓄積製剤
CN1849110A (zh) * 2002-10-25 2006-10-18 辉瑞产品公司 新型储库型注射剂
MXPA03009945A (es) 2002-11-05 2007-04-16 Lg Electronics Inc Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
WO2005107719A2 (en) 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
WO2007027273A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
EP1181018B1 (en) 2003-03-12
CZ20014230A3 (cs) 2002-08-14
KR100477782B1 (ko) 2005-03-21
SK16782001A3 (sk) 2002-09-10
TNSN00112A1 (fr) 2005-11-10
YU76701A (sh) 2005-07-19
KR20020048307A (ko) 2002-06-22
SK284590B6 (sk) 2005-07-01
UY26166A1 (es) 2000-12-29
GC0000190A (en) 2006-03-29
NZ514764A (en) 2004-04-30
AP1409A (en) 2005-06-13
WO2000072847A1 (en) 2000-12-07
MA26741A1 (fr) 2004-12-20
CR6506A (es) 2004-03-24
HN2000000071A (es) 2001-02-02
HRP20010878A2 (en) 2003-06-30
SI1181018T1 (en) 2003-06-30
CO5170458A1 (es) 2002-06-27
EE04704B1 (et) 2006-10-16
SV2001000085A (es) 2001-11-08
ZA200109692B (en) 2002-11-26
BG65367B1 (bg) 2008-04-30
IS2396B (is) 2008-08-15
EE200100633A (et) 2003-02-17
PL352826A1 (en) 2003-09-08
ES2191618T3 (es) 2003-09-16
CA2371550A1 (en) 2000-12-07
HK1046366B (zh) 2005-07-29
AU777413B2 (en) 2004-10-14
DE60001649D1 (de) 2003-04-17
HUP0201297A3 (en) 2005-09-28
PA8495801A1 (es) 2001-12-14
DK1181018T3 (da) 2003-04-22
GT200000081A (es) 2001-11-16
NO20015755D0 (no) 2001-11-26
RS50089B (sr) 2009-01-22
CN1352560A (zh) 2002-06-05
HK1046366A1 (en) 2003-01-10
GEP20033113B (en) 2003-11-25
CA2371550C (en) 2007-01-02
NO320296B1 (no) 2005-11-21
MY127891A (en) 2006-12-29
PL196867B1 (pl) 2008-02-29
JP3942827B2 (ja) 2007-07-11
IL145950A (en) 2007-12-03
DE60001649T2 (de) 2003-08-21
CU23223B7 (es) 2007-08-30
AP2001002346A0 (en) 2001-12-31
OA11946A (en) 2006-04-13
AU4138500A (en) 2000-12-18
UA59491C2 (uk) 2003-09-15
BG106153A (bg) 2002-06-28
EP1181018A1 (en) 2002-02-27
CN1196486C (zh) 2005-04-13
ATE234097T1 (de) 2003-03-15
BR0010990A (pt) 2002-03-05
EA200101131A1 (ru) 2002-04-25
AR022643A1 (es) 2002-09-04
HUP0201297A2 (en) 2002-08-28
JP2003500449A (ja) 2003-01-07
IL145950A0 (en) 2002-07-25
TWI263498B (en) 2006-10-11
TR200103392T2 (tr) 2002-11-21
HRP20010878B1 (en) 2007-03-31
PE20010127A1 (es) 2001-02-06
EA003907B1 (ru) 2003-10-30
MXPA01012124A (es) 2002-06-04
NO20015755L (no) 2002-01-23
IS6134A (is) 2001-10-30

Similar Documents

Publication Publication Date Title
DZ3049A1 (fr) Suspensions de ziprasidone nouvelles et procédé pour leur préparation.
DZ2826A1 (fr) Formulaons intranasales de mésylate de sildénafil et procédé pour leur préparation.
MA24529A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant .
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25493A1 (fr) Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
DZ3079A1 (fr) Procédé pour la préparation de 4-carboxy-amino-2-substitué-1,2,3,4 tétrahydroquinolé.
FR2795734B1 (fr) Conjugues d'erythropoietine,compositons les comprenant et procede pour leur preparation
ZA200106721B (en) Process for the manufacture of furfural.
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
CH689805A8 (fr) Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
DZ2114A1 (fr) Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.
DZ2420A1 (fr) Formulations nouvelles comprenant l'amoxycilline et du clavulanate et procédé pour leur préparation.
MA24484A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant .
DZ2894A1 (fr) Compositions pharmaceutiques contenant des dérivésde pyridol Ä1,2-AÜpyrazine et procédé pour leur p réparation.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EE200100574A (et) Uued ühendid, nende valmistamise meetod ning kasutamine
NO20013569L (no) Fremgangsmate ved fremstilling av L-fenylephrine-hydroklorid
FR2840307B1 (fr) Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
DZ2658A1 (fr) Formulations nouvelles de paroxétine et procédé pour leur préparation.
DZ2677A1 (fr) Compositions nouvelles renfermant des dérivés de benzopyranne et pyridopyranne et procédé pour leur préparation.
DZ3083A1 (fr) Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.